Home Trading ETFsStock Market P&G lifts sales forecast as price hikes, hygiene product demand continue By Reuters

P&G lifts sales forecast as price hikes, hygiene product demand continue By Reuters

by Reuters
2/2
© Reuters. FILE PHOTO: The logo for Procter & Gamble Co. is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., June 27, 2018. REUTERS/Brendan McDermid

2/2

(Reuters) -Procter & Gamble bumped up its annual sales forecast on Wednesday, as the consumer goods giant benefits from higher prices and resurgent cleaning products demand amid a spike in COVID-19 infections.

The company’s shares rose nearly 2% in premarket trading as strong quarterly sales helped cushion the blow from a bigger-than-previously forecast increase in annual freight and commodity costs.

Sales of fabric & home care products, including Tide and Mr. Clean, rose 7% in the second quarter, as the rapid spread of the Omicron coronavirus variant led consumers to buy more cleaning products.

A more intense flu season also drove organic demand for personal health care products up 20%.

This, along with price hikes to offset higher commodity and freight costs, boosted net sales by 6% to $20.95 billion. Analysts had expected $20.34 billion, according to Refinitiv IBES data.

Inflationary pressures are expected to continue for a while, P&G’ finance chief said after the company forecast a hit of $2.8 billion from commodity, freight and foreign exchange headwinds this year, up from $2.3 billion expected earlier.

P&G also raised its fiscal 2022 organic sales growth forecast to between 4% and 5%, from 2% and 4% earlier, and said it would buy back $9 billion to $10 billion worth of shares, compared with $7 billion to $9 billion expected earlier.

P&G also eased speculation that it could be interested in buying GlaxoSmithKline (NYSE:)’s consumer health business, which has drawn interest from European peer Unilever (NYSE:).

In a CNBC interview, CEO Jon Moeller said he was “very happy with its current portfolio” and saw no need for a large acquisition.

On Saturday, GSK rejected Unilever’s $68.4 billion offer for its consumer arm, calling it undervalued and saying it would stick to plans for a separate listing of the entity this year.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Related Articles

Leave a Comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy